Drugs / filapixant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03535168 | May 2018 → Sep 2019 | — | Bayer | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | filapixant | “we investigated the efficacy, safety, and tolerability of the novel selective P2X3 receptor antagonist filapixant (BAY1902607) in patients with refractory chronic cough.” PMID 37041539 ↗ Apr 2023 |
| Known as | BAY1902607 | “we investigated the efficacy, safety, and tolerability of the novel selective P2X3 receptor antagonist filapixant (BAY1902607) in patients with refractory chronic cough.” PMID 37041539 ↗ Apr 2023 |
| Action | Inhibit | “P2X3 receptor antagonist” PMID 37041539 ↗ Apr 2023 |
| Route | Oral | “ascending repeated oral doses of BAY1902607” NCT03535168 ↗ |